Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vebreltinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Apollomics Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Predicine Collaborates with Apollomics for Lung Cancer Companion Diagnostic
Details : The collaboration seeks to develop PredicineCARE, a blood cfDNA NGS assay to identify NSCLC patients who may benefit from therapy with APL-101 (vebreltinib), a small molecule c-Met inhibitor.
Brand Name : APL-101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 05, 2024
Lead Product(s) : Vebreltinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Apollomics Inc
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?